Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 31 entries
Sorted by: Best Match Show Resources per page
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Journal of hepatology

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N.
PMID: 34740705
J Hepatol. 2021 Nov 02; doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 02.

BACKGROUND & AIMS: EDP-305 is an oral farnesoid X receptor (FXR) agonist under development for treating nonalcoholic steatohepatitis (NASH). The efficacy, safety, and tolerability of EDP-305 was evaluated in a Phase 2, randomized, double-blind, placebo-controlled study.METHODS: Non-cirrhotic patients with...

Cite
Ratziu V, Rinella ME, Neuschwander-Tetri BA, et al. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2021;doi: 10.1016/j.jhep.2021.10.018.
Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., DeGrauw, J., Goodwin, B., Ahmad, A., & Adda, N. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of hepatology, . https://doi.org/10.1016/j.jhep.2021.10.018
Ratziu, Vlad, et al. "EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study." Journal of hepatology vol. (2021). doi: https://doi.org/10.1016/j.jhep.2021.10.018
Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2021 Nov 02; doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 02. PMID: 34740705.
Copy Download .nbib Format: NLM
NAFLD: Reporting Histologic Findings in Clinical Practice.

Hepatology (Baltimore, Md.)

Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ.
PMID: 33111374
Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599.

The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents. Drug development and clinical trials are rapidly growing, as are noninvasive tests...

Cite
Brunt EM, Kleiner DE, Carpenter DH, et al. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021;73(5):2028-2038doi: 10.1002/hep.31599.
Brunt, E. M., Kleiner, D. E., Carpenter, D. H., Rinella, M., Harrison, S. A., Loomba, R., Younossi, Z., Neuschwander-Tetri, B. A., Sanyal, A. J. (2021). NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology (Baltimore, Md.), 73(5), 2028-2038. https://doi.org/10.1002/hep.31599
Brunt, Elizabeth M, et al. "NAFLD: Reporting Histologic Findings in Clinical Practice." Hepatology (Baltimore, Md.) vol. 73,5 (2021): 2028-2038. doi: https://doi.org/10.1002/hep.31599
Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599. PMID: 33111374.
Copy Download .nbib Format: NLM
NAFLD: Reporting Histologic Findings in Clinical Practice.

Hepatology (Baltimore, Md.)

Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ.
PMID: 33111374
Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599.

The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents. Drug development and clinical trials are rapidly growing, as are noninvasive tests...

Cite
Brunt EM, Kleiner DE, Carpenter DH, et al. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021;73(5):2028-2038doi: 10.1002/hep.31599.
Brunt, E. M., Kleiner, D. E., Carpenter, D. H., Rinella, M., Harrison, S. A., Loomba, R., Younossi, Z., Neuschwander-Tetri, B. A., Sanyal, A. J. (2021). NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology (Baltimore, Md.), 73(5), 2028-2038. https://doi.org/10.1002/hep.31599
Brunt, Elizabeth M, et al. "NAFLD: Reporting Histologic Findings in Clinical Practice." Hepatology (Baltimore, Md.) vol. 73,5 (2021): 2028-2038. doi: https://doi.org/10.1002/hep.31599
Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 May;73(5):2028-2038. doi: 10.1002/hep.31599. PMID: 33111374.
Copy Download .nbib Format: NLM
Inappropriate Testing for Acute Viral Hepatitis Is Common-Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States.

The Ochsner journal

Hammami MB, Hussaini K, Chhaparia A, Khalid H, Chamberland R, Neuschwander-Tetri B.
PMID: 33071662
Ochsner J. 2020;20(3):293-298. doi: 10.31486/toj.19.0062.

No abstract available.

Cite
Hammami MB, Hussaini K, Chhaparia A, et al. Inappropriate Testing for Acute Viral Hepatitis Is Common-Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States. Ochsner J. 2020;20(3):293-298doi: 10.31486/toj.19.0062.
Hammami, M. B., Hussaini, K., Chhaparia, A., Khalid, H., Chamberland, R., & Neuschwander-Tetri, B. (2020). Inappropriate Testing for Acute Viral Hepatitis Is Common-Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States. The Ochsner journal, 20(3), 293-298. https://doi.org/10.31486/toj.19.0062
Hammami, Muhammad Bader, et al. "Inappropriate Testing for Acute Viral Hepatitis Is Common-Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States." The Ochsner journal vol. 20,3 (2020): 293-298. doi: https://doi.org/10.31486/toj.19.0062
Hammami MB, Hussaini K, Chhaparia A, Khalid H, Chamberland R, Neuschwander-Tetri B. Inappropriate Testing for Acute Viral Hepatitis Is Common-Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States. Ochsner J. 2020;20(3):293-298. doi: 10.31486/toj.19.0062. PMID: 33071662; PMCID: PMC7529134.
Copy Download .nbib Format: NLM
Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network.

Radiology. Artificial intelligence

Wang K, Mamidipalli A, Retson T, Bahrami N, Hasenstab K, Blansit K, Bass E, Delgado T, Cunha G, Middleton MS, Loomba R, Neuschwander-Tetri BA, Sirlin CB, Hsiao A.
PMID: 32582883
Radiol Artif Intell. 2019 Mar;1(2). doi: 10.1148/ryai.2019180022. Epub 2019 Mar 27.

PURPOSE: To assess feasibility of training a convolutional neural network (CNN) to automate liver segmentation across different imaging modalities and techniques used in clinical practice and apply this to enable automation of liver biometry.METHODS: We trained a 2D U-Net...

Cite
Wang K, Mamidipalli A, Retson T, et al. Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network. Radiol Artif Intell. 2019;1(2)doi: 10.1148/ryai.2019180022.
Wang, K., Mamidipalli, A., Retson, T., Bahrami, N., Hasenstab, K., Blansit, K., Bass, E., Delgado, T., Cunha, G., Middleton, M. S., Loomba, R., Neuschwander-Tetri, B. A., Sirlin, C. B., Hsiao, A. (2019). Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network. Radiology. Artificial intelligence, 1(2), . https://doi.org/10.1148/ryai.2019180022
Wang, Kang, et al. "Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network." Radiology. Artificial intelligence vol. 1,2 (2019). doi: https://doi.org/10.1148/ryai.2019180022
Wang K, Mamidipalli A, Retson T, Bahrami N, Hasenstab K, Blansit K, Bass E, Delgado T, Cunha G, Middleton MS, Loomba R, Neuschwander-Tetri BA, Sirlin CB, Hsiao A. Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network. Radiol Artif Intell. 2019 Mar;1(2). doi: 10.1148/ryai.2019180022. Epub 2019 Mar 27. PMID: 32582883; PMCID: PMC7314107.
Copy Download .nbib Format: NLM
An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis.

Hepatology communications

Ulmasov B, Noritake H, Carmichael P, Oshima K, Griggs DW, Neuschwander-Tetri BA.
PMID: 30766962
Hepatol Commun. 2018 Dec 27;3(2):246-261. doi: 10.1002/hep4.1298. eCollection 2019 Feb.

The presence and stage of liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) is strongly associated with mortality. Thus, both preventing and reversing fibrosis are critically important approaches to prevent death or the need for liver transplantation from NASH....

Cite
Ulmasov B, Noritake H, Carmichael P, et al. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol Commun. 2018;3(2):246-261doi: 10.1002/hep4.1298.
Ulmasov, B., Noritake, H., Carmichael, P., Oshima, K., Griggs, D. W., & Neuschwander-Tetri, B. A. (2019). An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatology communications, 3(2), 246-261. https://doi.org/10.1002/hep4.1298
Ulmasov, Barbara, et al. "An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis." Hepatology communications vol. 3,2 (2019): 246-261. doi: https://doi.org/10.1002/hep4.1298
Ulmasov B, Noritake H, Carmichael P, Oshima K, Griggs DW, Neuschwander-Tetri BA. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol Commun. 2018 Dec 27;3(2):246-261. doi: 10.1002/hep4.1298. eCollection 2019 Feb. PMID: 30766962; PMCID: PMC6357833.
Copy Download .nbib Format: NLM
Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

Journal of lipids

de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ.
PMID: 22132342
J Lipids. 2012;2012:302847. doi: 10.1155/2012/302847. Epub 2011 Nov 03.

The cholesterol absorption inhibitor ezetimibe can significantly reduce plasma cholesterol concentrations by inhibiting the Niemann-Pick C1-like 1 protein (NPC1L1), an intestinal sterol influx transporter that can actively facilitate the uptake of cholesterol for intestinal absorption. Unexpectedly, ezetimibe treatment also...

Cite
de Bari O, Neuschwander-Tetri BA, Liu M, et al. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2011;2012:302847doi: 10.1155/2012/302847.
de Bari, O., Neuschwander-Tetri, B. A., Liu, M., Portincasa, P., & Wang, D. Q. (2012). Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. Journal of lipids, 2012302847. https://doi.org/10.1155/2012/302847
de Bari, Ornella, et al. "Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease." Journal of lipids vol. 2012 (2012): 302847. doi: https://doi.org/10.1155/2012/302847
de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2012;2012:302847. doi: 10.1155/2012/302847. Epub 2011 Nov 03. PMID: 22132342; PMCID: PMC3216277.
Copy Download .nbib Format: NLM
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

Hepatology communications

Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ.
PMID: 34141981
Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of...

Cite
Barritt AS, Watkins S, Gitlin N, et al. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun. 2021;5(6):938-946doi: 10.1002/hep4.1689.
Barritt, A. S., Watkins, S., Gitlin, N., Klein, S., Lok, A. S., Loomba, R., Schoen, C., Reddy, K. R., Trinh, H. N., Mospan, A. R., Vos, M. B., Weiss, L. M., Cusi, K., Neuschwander-Tetri, B. A., & Sanyal, A. J. (2021). Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatology communications, 5(6), 938-946. https://doi.org/10.1002/hep4.1689
Barritt, A Sidney, et al. "Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study." Hepatology communications vol. 5,6 (2021): 938-946. doi: https://doi.org/10.1002/hep4.1689
Barritt AS, Watkins S, Gitlin N, Klein S, Lok AS, Loomba R, Schoen C, Reddy KR, Trinh HN, Mospan AR, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun. PMID: 34141981; PMCID: PMC8183178.
Copy Download .nbib Format: NLM
Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis.

Molecular metabolism

Mukherjee S, Chakraborty M, Ulmasov B, McCommis K, Zhang J, Carpenter D, Msengi EN, Haubner J, Guo C, Pike DP, Ghoshal S, Ford DA, Neuschwander-Tetri BA, Chakraborty A.
PMID: 34757046
Mol Metab. 2021 Oct 28;54:101364. doi: 10.1016/j.molmet.2021.101364. Epub 2021 Oct 28.

OBJECTIVE: Obesity and insulin resistance greatly increase the risk of nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH). We have previously discovered that whole-body and adipocyte-specific Ip6k1deletion protects mice from high-fat-diet-induced obesity and insulin resistance due to improved adipocyte thermogenesis...

Cite
Mukherjee S, Chakraborty M, Ulmasov B, et al. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Mol Metab. 2021;54:101364doi: 10.1016/j.molmet.2021.101364.
Mukherjee, S., Chakraborty, M., Ulmasov, B., McCommis, K., Zhang, J., Carpenter, D., Msengi, E. N., Haubner, J., Guo, C., Pike, D. P., Ghoshal, S., Ford, D. A., Neuschwander-Tetri, B. A., & Chakraborty, A. (2021). Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Molecular metabolism, 54101364. https://doi.org/10.1016/j.molmet.2021.101364
Mukherjee, Sandip, et al. "Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis." Molecular metabolism vol. 54 (2021): 101364. doi: https://doi.org/10.1016/j.molmet.2021.101364
Mukherjee S, Chakraborty M, Ulmasov B, McCommis K, Zhang J, Carpenter D, Msengi EN, Haubner J, Guo C, Pike DP, Ghoshal S, Ford DA, Neuschwander-Tetri BA, Chakraborty A. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Mol Metab. 2021 Oct 28;54:101364. doi: 10.1016/j.molmet.2021.101364. Epub 2021 Oct 28. PMID: 34757046; PMCID: PMC8609165.
Copy Download .nbib Format: NLM
Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis.

Molecular metabolism

Mukherjee S, Chakraborty M, Ulmasov B, McCommis K, Zhang J, Carpenter D, Msengi EN, Haubner J, Guo C, Pike DP, Ghoshal S, Ford DA, Neuschwander-Tetri BA, Chakraborty A.
PMID: 34757046
Mol Metab. 2021 Dec;54:101364. doi: 10.1016/j.molmet.2021.101364. Epub 2021 Oct 28.

OBJECTIVE: Obesity and insulin resistance greatly increase the risk of nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH). We have previously discovered that whole-body and adipocyte-specific Ip6k1deletion protects mice from high-fat-diet-induced obesity and insulin resistance due to improved adipocyte thermogenesis...

Cite
Mukherjee S, Chakraborty M, Ulmasov B, et al. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Mol Metab. 2021;54:101364doi: 10.1016/j.molmet.2021.101364.
Mukherjee, S., Chakraborty, M., Ulmasov, B., McCommis, K., Zhang, J., Carpenter, D., Msengi, E. N., Haubner, J., Guo, C., Pike, D. P., Ghoshal, S., Ford, D. A., Neuschwander-Tetri, B. A., & Chakraborty, A. (2021). Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Molecular metabolism, 54101364. https://doi.org/10.1016/j.molmet.2021.101364
Mukherjee, Sandip, et al. "Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis." Molecular metabolism vol. 54 (2021): 101364. doi: https://doi.org/10.1016/j.molmet.2021.101364
Mukherjee S, Chakraborty M, Ulmasov B, McCommis K, Zhang J, Carpenter D, Msengi EN, Haubner J, Guo C, Pike DP, Ghoshal S, Ford DA, Neuschwander-Tetri BA, Chakraborty A. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis. Mol Metab. 2021 Dec;54:101364. doi: 10.1016/j.molmet.2021.101364. Epub 2021 Oct 28. PMID: 34757046; PMCID: PMC8609165.
Copy Download .nbib Format: NLM
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.

Gastroenterology

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G.
PMID: 34310978
Gastroenterology. 2021 Nov;161(5):1475-1486. doi: 10.1053/j.gastro.2021.07.025. Epub 2021 Jul 23.

BACKGROUND & AIMS: Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid synthase inhibitor, was designed to reduce excess liver fat and directly inhibit inflammatory and fibrogenic pathways....

Cite
Loomba R, Mohseni R, Lucas KJ, et al. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021;161(5):1475-1486doi: 10.1053/j.gastro.2021.07.025.
Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., O'Farrell, M., McCulloch, W., Grimmer, K., Rinella, M., Wai-Sun Wong, V., Ratziu, V., Gores, G. J., Neuschwander-Tetri, B. A., & Kemble, G. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology, 161(5), 1475-1486. https://doi.org/10.1053/j.gastro.2021.07.025
Loomba, Rohit, et al. "TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial." Gastroenterology vol. 161,5 (2021): 1475-1486. doi: https://doi.org/10.1053/j.gastro.2021.07.025
Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 Nov;161(5):1475-1486. doi: 10.1053/j.gastro.2021.07.025. Epub 2021 Jul 23. PMID: 34310978.
Copy Download .nbib Format: NLM
Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple.

Hepatology communications

Yuan L, McCommis KS, Neuschwander-Tetri BA.
PMID: 34558836
Hepatol Commun. 2021 Aug 09; doi: 10.1002/hep4.1773. Epub 2021 Aug 09.

No abstract available.

Cite
Yuan L, McCommis KS, Neuschwander-Tetri BA. Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple. Hepatol Commun. 2021;doi: 10.1002/hep4.1773.
Yuan, L., McCommis, K. S., & Neuschwander-Tetri, B. A. (2021). Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple. Hepatology communications, . https://doi.org/10.1002/hep4.1773
Yuan, Liyun, et al. "Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple." Hepatology communications vol. (2021). doi: https://doi.org/10.1002/hep4.1773
Yuan L, McCommis KS, Neuschwander-Tetri BA. Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple. Hepatol Commun. 2021 Aug 09; doi: 10.1002/hep4.1773. Epub 2021 Aug 09. PMID: 34558836.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 31 entries